153 related articles for article (PubMed ID: 38780922)
1. Giving T-cell bispecifics a helping hand.
Kobold S
Blood; 2024 May; 143(21):2115-2116. PubMed ID: 38780922
[No Abstract] [Full Text] [Related]
2. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
[TBL] [Abstract][Full Text] [Related]
3. Redirected T Cell Cytotoxicity in Cancer Therapy.
Clynes RA; Desjarlais JR
Annu Rev Med; 2019 Jan; 70():437-450. PubMed ID: 30379598
[TBL] [Abstract][Full Text] [Related]
4. Bispecific antibodies for polyclonal T-cell engagement.
Baeuerle PA; Kufer P; Lutterbüse R
Curr Opin Mol Ther; 2003 Aug; 5(4):413-9. PubMed ID: 14513685
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies for immune cell retargeting against cancer.
Chen RP; Shinoda K; Rampuria P; Jin F; Bartholomew T; Zhao C; Yang F; Chaparro-Riggers J
Expert Opin Biol Ther; 2022 Aug; 22(8):965-982. PubMed ID: 35485219
[TBL] [Abstract][Full Text] [Related]
6. Bispecific T-cell engaging antibodies for cancer therapy.
Baeuerle PA; Reinhardt C
Cancer Res; 2009 Jun; 69(12):4941-4. PubMed ID: 19509221
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Antibody Armed T Cells to Target Cancer Cells.
Thakur A; Lum LG; Mittal S
Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.
Lussana F; Gritti G; Rambaldi A
J Clin Oncol; 2021 Feb; 39(5):444-455. PubMed ID: 33434063
[No Abstract] [Full Text] [Related]
9. Expanding the Reach of Bispecifics.
Cancer Discov; 2021 May; 11(5):1002. PubMed ID: 33766831
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.
Correnti CE; Laszlo GS; de van der Schueren WJ; Godwin CD; Bandaranayake A; Busch MA; Gudgeon CJ; Bates OM; Olson JM; Mehlin C; Walter RB
Leukemia; 2018 May; 32(5):1239-1243. PubMed ID: 29588544
[No Abstract] [Full Text] [Related]
11. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
12. Targeting T cells to tumor cells using bispecific antibodies.
Frankel SR; Baeuerle PA
Curr Opin Chem Biol; 2013 Jun; 17(3):385-92. PubMed ID: 23623807
[TBL] [Abstract][Full Text] [Related]
13. Bispecific antibodies and diabodies for cancer immunotherapy.
Elsässer-Beile U; Bühler P
Immunotherapy; 2012 May; 4(5):459-60. PubMed ID: 22642325
[No Abstract] [Full Text] [Related]
14. When B cells rebuff bispecifics.
Olszewski AJ
Blood; 2024 Feb; 143(9):744-746. PubMed ID: 38421818
[No Abstract] [Full Text] [Related]
15. BiTEs: bispecific antibody constructs with unique anti-tumor activity.
Wolf E; Hofmeister R; Kufer P; Schlereth B; Baeuerle PA
Drug Discov Today; 2005 Sep; 10(18):1237-44. PubMed ID: 16213416
[TBL] [Abstract][Full Text] [Related]
16. BiTEing the Tumor.
Kumar S; Rajkumar SV
J Clin Oncol; 2020 Jun; 38(18):2077-2079. PubMed ID: 32374643
[No Abstract] [Full Text] [Related]
17. Merck KGaA, F-Star shake on immune-oncology bispecifics.
Nat Biotechnol; 2017 Jul; 35(7):601. PubMed ID: 28700541
[No Abstract] [Full Text] [Related]
18. Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy.
Schirrmacher V; Haas C
Adv Exp Med Biol; 1998; 451():251-7. PubMed ID: 10026882
[No Abstract] [Full Text] [Related]
19. Activated T cells armed with bispecific antibodies kill tumor targets.
Bhutani D; Lum LG
Curr Opin Hematol; 2015 Nov; 22(6):476-83. PubMed ID: 26457960
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibodies.
Brinkmann U; Kontermann RE
Science; 2021 May; 372(6545):916-917. PubMed ID: 34045345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
